Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...
About one in nine adults suffer from chronic insomnia and its residual effects like drowsiness, cognitive issues, and ...
POWELL, OH - January 08, 2026 - PRESSADVANTAGE - Be Aligned Health, a chiropractic office based in Powell, Ohio, ...
From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...
MINNEAPOLIS, MN, UNITED STATES, January 8, 2026 /EINPresswire.com/ -- Versique Executive, Professional & Interim ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of ...
Swift and Standard Chartered unveil blockchain ledger to connect tokenized assets across 200+ countries, bridging traditional ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea (narsoplimab-wuug) for hematopoietic stem cell transplant-associated thrombotic ...
BRADENTON, FL - January 08, 2026 - PRESSADVANTAGE - Wave Chiropractic highlights sports chiropractic care as a key ...
Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from ...
It's been a long time coming: Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the Seattle biotech has finally scored its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback